CRL

215.75

1.43% 3.04

Dopo l'orario di chiusura: 215.75

Charles River Laboratories International Inc (CRL)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$212.71

Aprire:

$210

Volume 24 ore:

1.45M

Relative Volume:

1.65

Capitalizzazione di mercato:

$10.39B

Reddito:

$4.03B

Utile/perdita netta:

$-182.84M

Rapporto P/E:

-57.38

EPS:

-3.7603

Flusso di cassa netto:

$391.29M

1 W Prestazione:

+16.62%

1M Prestazione:

+37.66%

6M Prestazione:

+5.94%

1 anno Prestazione:

+42.32%

Intervallo 1D:

$210.00

$217.19

Intervallo di 1 settimana:

$178.92

$217.19

Portata 52W:

$144.26

$228.88

Charles River Laboratories International Inc Stock (CRL) Company Profile

Nome

Charles River Laboratories International Inc

Settore

Healthcare (1096)

Industria

Diagnostics & Research (48)

Telefono

781-222-6000

Indirizzo

251 BALLARDVALE ST, WILMINGTON, MA

Dipendente

19,700

Cinguettio

@criverlabs

Prossima data di guadagno

2026-08-05

Ultimi documenti SEC

CRL's Discussions on Twitter

Compare CRL vs TMO, DHR, IDXX, A, NTRA

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
CRL Charles River Laboratories International Inc	215.75	10.25B	4.03B	-182.84M	391.29M	-3.7603
TMO Thermo Fisher Scientific Inc	513.03	187.95B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	196.19	136.75B	24.78B	3.68B	5.29B	5.1743
IDXX Idexx Laboratories Inc	551.50	43.78B	4.45B	1.10B	1.06B	13.59
A Agilent Technologies Inc	136.01	38.27B	7.23B	1.41B	1.09B	4.979
NTRA Natera Inc	261.91	37.34B	2.50B	-226.32M	71.51M	-1.6412

Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-06-17	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2026-05-29	Aggiornamento	CLSA	Hold → Outperform
2026-04-14	Iniziato	RBC Capital Mkts	Outperform
2025-12-15	Aggiornamento	BofA Securities	Neutral → Buy
2025-11-17	Aggiornamento	Argus	Hold → Buy
2025-11-06	Aggiornamento	Robert W. Baird	Neutral → Outperform
2025-10-06	Aggiornamento	William Blair	Mkt Perform → Outperform
2025-10-02	Aggiornamento	Barclays	Equal Weight → Overweight
2025-09-09	Aggiornamento	Jefferies	Hold → Buy
2025-07-09	Aggiornamento	Citigroup	Neutral → Buy
2025-05-23	Aggiornamento	Redburn Atlantic	Neutral → Buy
2025-05-14	Aggiornamento	TD Cowen	Hold → Buy
2025-05-08	Aggiornamento	Evercore ISI	In-line → Outperform
2025-03-21	Downgrade	Goldman	Buy → Neutral
2025-03-04	Aggiornamento	Citigroup	Sell → Neutral
2025-03-03	Aggiornamento	Redburn Atlantic	Sell → Neutral
2025-01-22	Downgrade	William Blair	Outperform → Mkt Perform
2025-01-17	Downgrade	UBS	Buy → Neutral
2024-11-18	Downgrade	CLSA	Hold → Underperform
2024-11-07	Aggiornamento	CLSA	Underperform → Hold
2024-10-23	Iniziato	CLSA	Underperform
2024-10-14	Iniziato	Redburn Atlantic	Sell
2024-10-07	Downgrade	Evercore ISI	Outperform → In-line
2024-10-02	Downgrade	BofA Securities	Buy → Neutral
2024-10-01	Downgrade	Citigroup	Neutral → Sell
2024-08-08	Downgrade	JP Morgan	Overweight → Neutral
2024-08-08	Downgrade	Robert W. Baird	Outperform → Neutral
2024-06-28	Downgrade	Argus	Buy → Hold
2024-06-07	Iniziato	Mizuho	Neutral
2024-06-06	Iniziato	Goldman	Buy
2024-02-15	Downgrade	Guggenheim	Buy → Neutral
2023-09-13	Iniziato	TD Cowen	Market Perform
2023-07-10	Downgrade	Citigroup	Buy → Neutral
2023-02-23	Aggiornamento	Guggenheim	Neutral → Buy
2023-01-12	Downgrade	Jefferies	Buy → Hold
2022-09-30	Aggiornamento	Jefferies	Hold → Buy
2022-08-25	Iniziato	Credit Suisse	Outperform
2022-08-04	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2022-05-24	Iniziato	Guggenheim	Neutral
2022-04-25	Downgrade	Jefferies	Buy → Hold
2022-04-07	Iniziato	Stephens	Overweight
2022-02-17	Reiterato	BofA Securities	Buy
2022-02-17	Aggiornamento	Citigroup	Neutral → Buy
2022-02-17	Reiterato	Deutsche Bank	Buy
2022-02-17	Reiterato	Morgan Stanley	Overweight
2022-02-17	Reiterato	UBS	Buy
2021-08-05	Ripresa	Credit Suisse	Neutral
2020-12-16	Downgrade	Citigroup	Buy → Neutral
2020-09-10	Aggiornamento	Jefferies	Hold → Buy
2020-07-01	Aggiornamento	BofA Securities	Neutral → Buy
2020-05-13	Aggiornamento	UBS	Neutral → Buy
2020-04-21	Downgrade	Jefferies	Buy → Hold
2020-03-27	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2020-03-02	Iniziato	Deutsche Bank	Buy
2020-02-18	Aggiornamento	Wolfe Research	Peer Perform → Outperform
2020-01-10	Aggiornamento	Goldman	Neutral → Buy
2020-01-08	Iniziato	Wells Fargo	Overweight
2020-01-07	Iniziato	Citigroup	Buy
2019-10-18	Downgrade	BofA/Merrill	Buy → Neutral
2019-06-10	Iniziato	SVB Leerink	Outperform
2019-04-30	Ripresa	Evercore ISI	Outperform
2018-12-14	Iniziato	Deutsche Bank	Buy
2018-10-09	Iniziato	UBS	Neutral
2018-08-23	Aggiornamento	Raymond James	Mkt Perform → Outperform
2018-07-17	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2018-06-15	Aggiornamento	KeyBanc Capital Mkts	Sector Weight → Overweight
2018-02-14	Aggiornamento	SunTrust	Hold → Buy

Mostra tutto

Charles River Laboratories International Inc Borsa (CRL) Ultime notizie

07:33 AM

Charles River Laboratories lands Morgan Stanley upgrade, shares in analyst focus - Ad-hoc-news.de

07:33 AM

06:26 AM

Enterprise value to revenue forward of Charles River Laboratories International, Inc. – NYSE:CRL - TradingView

06:26 AM

02:48 AM

Enterprise value to revenue forward of Charles River Laboratories International, Inc. – DUS:RV6 - TradingView

02:48 AM

Jun 26, 2026

Enterprise value to EBIT forward of Charles River Laboratories International, Inc. – NYSE:CRL - TradingView

Jun 26, 2026

Enterprise value to EBIT forward of Charles River Laboratories International, Inc. – MUN:RV6 - TradingView

Jun 26, 2026

Charles River Laboratories International Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch

Jun 26, 2026

RV6 Forecast — Price Target — Prediction for 2027 - TradingView

Jun 26, 2026